Christopher Wood

Christopher Wood at MD Anderson has contributed to renal cell carcinoma surgical management, including research on cytoreductive nephrectomy for metastatic RCC in the targeted therapy era. The CARMENA trial's finding that sunitinib alone was non-inferior to nephrectomy plus sunitinib in metastatic RCC challenged the practice of routine cytoreductive nephrectomy, and ongoing research seeks to identify which patients benefit from surgery in the IO combination era.